Skip Nav Destination
Issues
15 August 2013
-
Cover Image
Cover Image
The actin cytoskeleton, due to its role in many processes involved in cellular transformation, has long been a sought after anticancer target, yet attempts to develop such compounds have been hampered by unacceptable toxicity. By targeting the other core polymer system of the microfilaments, tropomyosin, it is possible to discriminate between actin filaments required for sarcomeric function and those required for tumor growth. In silico modeling shows the predicted association of the first in class anti-tropomyosin compound, TR100, with the C-terminus of a cancer-associated tropomyosin, Tm5NM1. The interaction between Tm5NM1 and TR100 results in disruption of actin filament organization and death of tumor cells, both in vitro and in vivo. For details, see article by Stehn and colleagues on page 5169.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 0008-5472
EISSN 1538-7445
Journal Archive
Cancer Research (1941-Present; volumes 1-current)
(ISSN 0008-5472) Published twice monthly since 1987. From 1941-1986, published monthly.The American Journal of Cancer (1931-1940; volumes 15-40)
(ISSN 0099-7374) Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.The Journal of Cancer Research (1916-1930); volumes 1-14)
(ISSN 0099-7013) Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.Table of Contents
Breaking Advances
Reviews
Perspective
Meeting Report
Integrated Systems and Technologies
Microenvironment and Immunology
Molecular and Cellular Pathobiology
Gene Profiling of Canine B-Cell Lymphoma Reveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times, Modeling Human DLBCL
Kristy L. Richards; Alison A. Motsinger-Reif; Hsiao-Wei Chen; Yuri Fedoriw; Cheng Fan; Dahlia M. Nielsen; George W. Small; Rachael Thomas; Chris Smith; Sandeep S. Dave; Charles M. Perou; Matthew Breen; Luke B. Borst; Steven E. Suter
DDB2: A Novel Regulator of NF-κB and Breast Tumor Invasion
Marie Ennen; Rémi Klotz; Nadège Touche; Sophie Pinel; Claire Barbieux; Vanessa Besancenot; Emilie Brunner; Denise Thiebaut; Alain C. Jung; Sonia Ledrappier; Lionel Domenjoud; Joseph Abecassis; François Plénat; Stéphanie Grandemange; Philippe Becuwe
Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer
Meagan J. McGrath; Lauren C. Binge; Absorn Sriratana; Hong Wang; Paul A. Robinson; David Pook; Clare G. Fedele; Susan Brown; Jennifer M. Dyson; Denny L. Cottle; Belinda S. Cowling; Birunthi Niranjan; Gail P. Risbridger; Christina A. Mitchell
Author Choice
The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis
Sergei Boichuk; Joshua A. Parry; Kathleen R. Makielski; Larisa Litovchick; Julianne L. Baron; James P. Zewe; Agnieszka Wozniak; Keith R. Mehalek; Nina Korzeniewski; Danushka S. Seneviratne; Patrick Schöffski; Maria Debiec-Rychter; James A. DeCaprio; Anette Duensing
Prevention and Epidemiology
Therapeutics, Targets, and Chemical Biology
Author Choice
A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells
Justine R. Stehn; Nikolas K. Haass; Teresa Bonello; Melissa Desouza; Gregg Kottyan; Herbert Treutlein; Jun Zeng; Paula R.B.B. Nascimento; Vanessa B. Sequeira; Tanya L. Butler; Munif Allanson; Thomas Fath; Timothy A. Hill; Adam McCluskey; Galina Schevzov; Stephen J. Palmer; Edna C. Hardeman; David Winlaw; Vivienne E. Reeve; Ian Dixon; Wolfgang Weninger; Timothy P. Cripe; Peter W. Gunning
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
Christian Mirschberger; Christian B. Schiller; Michael Schräml; Nikolaos Dimoudis; Thomas Friess; Christian A. Gerdes; Ulrike Reiff; Valeria Lifke; Gabriele Hoelzlwimmer; Irene Kolm; Karl-Peter Hopfner; Gerhard Niederfellner; Birgit Bossenmaier
Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Rachel G. Liao; Joonil Jung; Jeremy Tchaicha; Matthew D. Wilkerson; Andrey Sivachenko; Ellen M. Beauchamp; Qingsong Liu; Trevor J. Pugh; Chandra Sekhar Pedamallu; D. Neil Hayes; Nathanael S. Gray; Gad Getz; Kwok-Kin Wong; Robert I. Haddad; Matthew Meyerson; Peter S. Hammerman
Tumor and Stem Cell Biology
Author Choice
JAK-STAT Blockade Inhibits Tumor Initiation and Clonogenic Recovery of Prostate Cancer Stem-like Cells
Paula Kroon; Paul A. Berry; Michael J. Stower; Greta Rodrigues; Vincent M. Mann; Matthew Simms; Deepak Bhasin; Somsundaram Chettiar; Chenglong Li; Pui-Kai Li; Norman J. Maitland; Anne T. Collins
Advertisement